These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37465818)

  • 1. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
    Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
    J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT; Whalen J; Seewoodharry Buguth B; Vallejo-Aparicio LA; Naya IP; Asukai Y; Alcázar-Navarrete B; Miravitlles M; García-Río F; Risebrough NA
    Respir Res; 2018 Nov; 19(1):224. PubMed ID: 30458866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
    Alcázar Navarrete B; Boucot I; Naya I; Tombs L; Lipson DA; Compton C; Sousa AR; Feldman G
    Pulm Ther; 2018 Dec; 4(2):171-183. PubMed ID: 32026389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
    BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
    Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
    Miravitlles M; Gáldiz JB; Huerta A; Villacampa A; Carcedo D; Garcia-Rio F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():123-32. PubMed ID: 26848262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF; Beeh KM; Schultze M; Kossack N; Richter LM; Claussen J; Compton C; Noorduyn SG; Ismaila AS; Requena G
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1835-1848. PubMed ID: 39140078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo C; Yeap J; Wild R; Compton C; Rothnie KJ; Herth FJF; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2039-2054. PubMed ID: 37731774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
    Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
    Pulm Ther; 2021 Jun; 7(1):203-219. PubMed ID: 33728597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
    McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
    Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
    Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
    Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
    Zhou Y; Duan S; Zhang L; Peng F
    Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF; Niewoehner D; Brooks J; O'Dell D; Church A
    Respir Res; 2014 Jul; 15(1):78. PubMed ID: 25015176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.